文献速递糖尿病

SGLT2抑制剂使用者的急性肾损伤:倾向性匹配分析

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
PubMed 文献 · Diabetes Care · 2017-08-21

研究利用西奈山慢性肾脏病登记和Geisinger健康系统两个队列的纵向数据,比较2型糖尿病患者中使用与未使用SGLT2抑制剂的急性肾损伤(AKI)风险。经1:1倾向性匹配后,西奈山队列使用者AKI风险降低(HR 0.4),Geisinger队列未调整风险降低(HR 0.5)但调整后未达统计学显著(aHR 0.6)。结论提示SGLT2抑制剂使用未增加AKI风险。

要点

  • 西奈山队列中SGLT2抑制剂使用者AKI风险较未使用者降低60%(HR 0.4,95%CI 0.2-0.7)。
  • Geisinger队列调整后AKI风险未达统计学显著(aHR 0.6,95%CI 0.4-1.1,P=0.09)。
  • 两个大型健康系统的数据均未提示SGLT2抑制剂增加AKI风险。

核心结论

  • 在两个大型健康系统的2型糖尿病患者中,研究结果未提示SGLT2抑制剂使用与急性肾损伤风险增加相关。

研究设计与样本

  • 研究使用西奈山慢性肾脏病登记和Geisinger健康系统队列的纵向数据,纳入SGLT2抑制剂使用者和未使用者(2型糖尿病无SGLT2抑制剂处方)。
  • AKI采用KDIGO定义(AKIKDIGO)判定。
  • 进行1:1最近邻倾向性匹配,计算未调整和调整(针对平衡不佳的协变量)的风险比(HR)。
  • 西奈山队列识别377例SGLT2抑制剂使用者和377例未使用者。
  • Geisinger队列识别1207例SGLT2抑制剂使用者和1207例未使用者。

主要发现

  • 西奈山队列中,SGLT2抑制剂使用者3.8% vs 未使用者9.7%发生AKIKDIGO事件,中位随访14个月。
  • 西奈山队列未调整HR 0.4(95%CI 0.2-0.7;P=0.01),调整后aHR 0.4(95%CI 0.2-0.7;P=0.004)。
  • Geisinger队列中,SGLT2抑制剂使用者2.2% vs 未使用者4.6%发生AKIKDIGO事件。
  • Geisinger队列未调整HR 0.5(95%CI 0.3-0.8;P<0.01),调整后aHR 0.6(95%CI 0.4-1.1;P=0.09),未达统计学显著。
  • 多项敏感性分析结果定性不变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are new medications that improve cardiovascular and renal outcomes in patients with type 2 diabetes (T2D). However, the Food and Drug Administration has issued alerts regarding increased acute kidney injury (AKI) risk with canagliflozin and dapagliflozin. We aimed to assess the real-world risk of AKI in new SGLT2 inhibitor users in two large health care utilization cohorts of patients with T2D. RESEARCH DESIGN AND METHODS: We used longitudinal data from the Mount Sinai chronic kidney disease registry and the Geisinger Health System cohort. We selected SGLT inhibitor users and nonusers (patients with T2D without SGLT2 inhibitor prescription). We determined AKI by the KDIGO (Kidney Disease: Improving Global Outcomes) definition (AKIKDIGO). We performed 1:1 nearest-neighbor propensity matching and calculated unadjusted hazard ratios (HRs) and adjusted HRs (aHRs; accounting for covariates poorly balanced) for AKI in primary and sensitivity analyses. RESULTS: We identified 377 SGLT2 inhibitor users and 377 nonusers in the Mount Sinai cohort, of whom 3.8 and 9.7%, respectively, had an AKIKDIGO event over a median follow-up time of 14 months. The unadjusted hazards of AKIKDIGO were 60% lower in users (HR 0.4 [95% CI 0.2-0.7]; P = 0.01), which was unchanged (aHR 0.4 [95% CI 0.2-0.7]; P = 0.004) postadjustment. Similarly, we identified 1,207 SGLT2 inhibitor users and 1,207 nonusers in the Geisinger cohort, of whom 2.2 and 4.6% had an AKIKDIGO event. AKIKDIGO unadjusted hazards were lower in users (HR 0.5 [95% CI 0.3-0.8]; P < 0.01) with modest attenuation postadjustment for covariates (aHR 0.6 [95% CI 0.4-1.1]; P = 0.09). These estimates did not qualitatively change across several sensitivity analyses. CONCLUSIONS: Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with T2D in two large health systems.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nadkarni GN, Ferrandino R, Chang A, et al. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care. 2017. PMID: 28827404. doi:10.2337/dc17-1011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。